Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. The company was beleaguered with ...

Danaher Corporation’s DHR second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of $1.64 ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Insights from Steven Cohen (Trades, Portfolio)'s First Quarter 2025 13F Filing. Warning! GuruFocus has detected 4 Warning ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...

The stock's fall snapped a two-day winning streak.

The industrial and medical device maker posted revenue of $5.94 billion in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $5.84 billion. Danaher expects full ...

Danaher Corporation (DHR)’s share was trading at $202.62 as of 10 th June. DHR’s trailing and forward P/E were 38.6 and 26.39 respectively according to Yahoo Finance.

This was the stock's third consecutive day of losses.